前列腺癌的早期诊断和预后评估的研究进展
Research Progress in Early Diagnosis and Prognostic Evaluation of Prostate Cancer
DOI: 10.12677/ACM.2023.13112479, PDF,    国家自然科学基金支持
作者: 达尼亚尔·努尔德别克, 木拉提·热夏提, 张炜杰, 乔炳璋, 阿卜杜热合曼·则比布拉*：新疆医科大学第一附属医院泌尿外科，新疆 乌鲁木齐
关键词: 前列腺癌；微小RNA (miRNA)；肿瘤；Prostate Cancer； MicroRNA (miRNA)； Tumor
摘要: 前列腺癌是男性最常见的恶性肿瘤之一，其发病率在我国呈快速上升的趋势，早期精准诊断及预后评估是前列腺癌重要的研究热点。作为具有基因表达调控功能的非编码RNA，微核糖核酸(miRNAs)在前列腺癌中研究不断。近年来研究表明，前列腺癌中异常表达的miRNAs可通过调控癌基因、抑癌基因等方式在前列腺癌的发生发展过程中起到关键作用。其中，部分miRNAs可作为前列腺癌的非侵入性生物标记物，对前列腺癌的早期精准诊断及预后评估有重要的研究及临床应用价值。本文总结前列腺癌患者血液、尿液和肿瘤组织中特异性表达且可用作生物标志物的miRNA，并综述其在前列腺癌的早期诊断和预后评估中的相关基础和临床研究工作。
Abstract: Prostate cancer is one of the most common malignant tumors in men, and its incidence is rapidly increasing in China. Early precise diagnosis and prognosis evaluation are important research hotspots in prostate cancer. As a kind of non-coding RNAs possessing gene expression regulation functions, microRNAs (miRNAs) have been continuously studied in prostate cancer. Recent studies show that abnormally expressed miRNAs in prostate cancer can play key roles in occurrence and progress of prostate cancer by regulating oncogenes and oncogenes. Among them, some miRNAs can be used as non-invasive biomarkers for prostate cancer, which have important research and clinical application value for early and accurate diagnosis and prognosis evaluation. This work summarizes the miRNAs that can be used as biomarkers and specifically expressed in the blood, urine and tumor tissues of patients with prostate cancer, and further reviews their related basic and clinical research work in the early diagnosis and prognosis evaluation of prostate cancer.
文章引用：达尼亚尔·努尔德别克, 木拉提·热夏提, 张炜杰, 乔炳璋, 阿卜杜热合曼·则比布拉. 前列腺癌的早期诊断和预后评估的研究进展[J]. 临床医学进展, 2023, 13(11): 17676-17684. https://doi.org/10.12677/ACM.2023.13112479

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Liu, J., Dong, L., Zhu, Y., et al. (2022) Prostate Cancer Treat-ment—China’s Perspective. Cancer Letters, 550, Article ID: 215927. [Google Scholar] [CrossRef] [PubMed]
[3] 雷海科, 宋彦平, 李小升, 等. 前列腺癌患者生存随访调查及预后影响因素研究[J]. 中国男科学杂志, 2020, 34(2): 8-14.
[4] Rao, K., Liang, S., Cardamone, M., et al. (2018) Cost Implications of PSA Screening Differ by Age. Bmc Urology, 18, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[5] 雷银, 吴汶钊, 李天杰, 等. 前列腺穿刺与前列腺癌根治术后Gleason评分的比较[J]. 现代泌尿生殖肿瘤杂志, 2020, 12(6): 338-342.
[6] Kurhanewicz, J., Jung, A.J. and Vigneron, D.B. (2013) Role of Imaging as an Adjunct or Replacement for Biopsy: American Experience. In: Jones, J. Ed., Prostate Cancer Diagnosis. Current Clinical Urology. Humana Press, Totowa. [Google Scholar] [CrossRef] 
[7] 任秀娟, 红华, 周亮强, 等. 超声影像组学联合临床指标预测前列腺癌[J]. 中国超声医学杂志, 2022, 38(2): 196-200.
[8] Lone, S.N., Nisar, S., Masoodi, T., et al. (2022) Liquid Biopsy: A Step Closer to Transform Diagnosis, Prognosis and Future of Cancer Treatments. Molecular Cancer, 21, Article No. 79. [Google Scholar] [CrossRef] [PubMed]
[9] Li, W., Liu, J.B., Hou, L.K., et al. (2022) Liquid Biopsy in Lung Cancer: Significance in Diagnostics, Prediction, and Treatment Monitoring. Molecular Cancer, 21, 25.
[10] Yu, W., Hurley, J., Roberts, D., et al. (2021) Exosome-Based Liquid Biopsies in Cancer: Opportunities and Challenges. Annals of Oncology, 32, 466-477. [Google Scholar] [CrossRef] [PubMed]
[11] Coradduzza, D., Cruciani, S., Arru, C., et al. (2022) Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer. International Journal of Molecular Sciences, 23, Article 1626. [Google Scholar] [CrossRef] [PubMed]
[12] Menon, A., Abd-Aziz, N., Khalid, K., Poh, C.L., Naidu, R. (2022) miRNA: A Promising Therapeutic Target in Cancer. International Journal of Molecular Sciences, 23, Article 11502. [Google Scholar] [CrossRef] [PubMed]
[13] Volinia, S., Calin, G.A., Liu, C.G., et al. (2006) A microRNA Expression Signature of Human Solid Tumors Defines Cancer Gene Targets. Proceed-ings of the National Academy of Sciences of the United States of America, 103, 2257-2261. [Google Scholar] [CrossRef] [PubMed]
[14] Groen, L. and Schalken, J. (2022) Liquid Biopsy for Prostate and Bladder Cancer: Progress and Pitfalls. European Urology Focus, 8, 904-906. [Google Scholar] [CrossRef] [PubMed]
[15] Crocetto, F., Russo, G., Di Zazzo, E., et al. (2022) Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives. Cancers, 14, Article 3272. [Google Scholar] [CrossRef] [PubMed]
[16] Chen, X., Ba, Y., Ma, L., et al. (2008) Characterization of mi-croRNAs in Serum: A Novel Class of Biomarkers for Diagnosis of Cancer and Other Diseases. Cell Research, 18, 997-1006. [Google Scholar] [CrossRef] [PubMed]
[17] Lan, H., Lu, H., Wang, X. and Jin, H. (2015) MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges. BioMed Research International, 2015, Article ID: 125094. [Google Scholar] [CrossRef] [PubMed]
[18] Fabris, L., Ceder, Y., Chinnaiyan, A.M., et al. (2016) The Potential of MicroRNAs as Prostate Cancer Biomarkers. European Urology, 70, 312-322. [Google Scholar] [CrossRef] [PubMed]
[19] Ambs, S., Prueitt, R.L., Yi, M., et al. (2008) Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer. Cancer Research, 68, 6162-6170. [Google Scholar] [CrossRef] 
[20] Porkka, K.P., Pfeiffer, M.J., Waltering, K.K. , et al. (2007) Research Article MicroRNA Expression Profiling in Prostate Cancer. Cancer Research, 67, 6130-6135. [Google Scholar] [CrossRef] 
[21] 黄俊, 王清华, 郭佳. 前列腺癌诊断和预后相关生物标志物的研究进展[J]. 现代泌尿生殖肿瘤杂志, 2021, 13(6): 375-378.
[22] Moltzahn, F., Olshen, A.B., Baehner, L., et al. (2011) Microfluidic-Based Multiplex qRT-PCR Identifies Diagnostic and Prognostic microRNA Signatures in the Sera of Prostate Cancer Patients. Cancer Research, 71, 550-560. [Google Scholar] [CrossRef] 
[23] Bryant, R.J., Pawlowski, T., Catto, J., et al. (2012) Changes in Circulating microRNA Levels Associated with Prostate Cancer. British Journal of Cancer, 106, 768-74. [Google Scholar] [CrossRef] [PubMed]
[24] Li, Z., Ma, Y.Y., Wang, J., et al. (2015) Exosomal microRNA-141 Is Upregulated in the Serum of Prostate Cancer Patients. OncoTargets and Therapy, 9, 139-148. [Google Scholar] [CrossRef] 
[25] Endzeliņš, E., Berger, A., Melne, V., et al. (2017) Detection of Circulat-ing miRNAs: Comparative Analysis of Extracellular Vesicle-Incorporated miRNAs and Cell-Free miRNAs in Whole Plasma of Prostate Cancer Patients. BMC Cancer, 17, Article No. 730. [Google Scholar] [CrossRef] [PubMed]
[26] Chen, Z.H., Zhang, G.L., Li, H.R., et al. (2012) A Panel of Five Circulating microRNAs as Potential Biomarkers for Prostate Cancer. Prostate, 72, 1443-1452. [Google Scholar] [CrossRef] [PubMed]
[27] 史浩天, 范学武, 田龙, 胡逸民. miRNA-182与miRNA-187联合检测对前列腺癌诊断的价值[J]. 国际检验医学杂志, 2022, 43(6): 759-762.
[28] 任超. 尿液中miRNA-24-3p联合miRNA-222-3p检测在前列腺癌中的诊断及临床意义[J]. 天津医科大学学报, 2022, 28(2): 181-185.
[29] Llorente, A., Skotland, T., Sylv?Nne, T., et al. (2013) Molecular Lipidomics of Exosomes Released by PC-3 Prostate Cancer Cells. Biochimica et Biophysica Acta (BBA) —Molecular and Cell Biology of Lipids, 1831, 1302-1309. [Google Scholar] [CrossRef] [PubMed]
[30] Rodríguez, M., Bajo-Santos, C., Hessvik, N.P., et al. (2017) Identification of Non-Invasive miRNAs Biomarkers for Prostate Cancer by Deep Sequencing Analysis of Urinary Exo-somes. Molecular Cancer, 16, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
[31] Pellegrini, K.L., Patil, D., Douglas, K.J.S., et al. (2017) Detection of Prostate Cancer-Specific Transcripts in Extracellular Vesicles Isolated from Post-DRE Urine. Prostate, 77, 990-999. [Google Scholar] [CrossRef] [PubMed]
[32] McKiernan, J., Donovan, M.J., O’Neill, V., et al. (2016) A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncology, 2, 882-889. [Google Scholar] [CrossRef] [PubMed]
[33] 张国颖, 李俊, 白宇, 等. miR-183通过抑制CAND1促进前列腺癌病理进程[J]. 中国老年学杂志, 2022, 42(3): 698-701.
[34] Konoshenko, M.Y., Bryzgunova, O.E. and Lak-tionov, P.P. (2021) miRNAs and Androgen Deprivation Therapy for Prostate Cancer. Biochimica et Biophysica Acta (BBA) —Reviews on Cancer, 1876, Article ID: 188625. [Google Scholar] [CrossRef] [PubMed]
[35] 张泉波, 李玉莲, 陈绮, 张艳艳, 陈国荣. 基于TCGA数据库构建前列腺癌相关miRNA预后模型[J]. 浙江医学, 2021, 43(18): 1971-1978+2049-2050.
[36] Huang, X., Yuan, T., Liang, M., et al. (2015) Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-Resistant Prostate Cancer. European Urology, 67, 33-41. [Google Scholar] [CrossRef] [PubMed]
[37] Wani, S., Kaul, D., Mavuduru, R.S., Kakkar, N. and Bhatia, A. (2017) Urinary-Exosomal miR-2909: A Novel Pathognomonic Trait of Prostate Cancer Severity. Journal of Biotechnology, 259, 135-139. [Google Scholar] [CrossRef] [PubMed]
[38] Foj, L., Ferrer, F., Serra, M., et al. (2017) Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis. Prostate, 77, 573-583. [Google Scholar] [CrossRef] [PubMed]
[39] Albino, D., Falcione, M., Uboldi, V., et al. (2021) Circulating Extracellular Vesicles Release Oncogenic miR-424 in Experimental Models and Patients with Aggressive Prostate Cancer. Communi-cations Biology, 4, Article No. 119. [Google Scholar] [CrossRef] [PubMed]
[40] Larne, O., Martens-Uzunova, E., Hagman, Z., et al. (2013) miQ—A Novel microRNA Based Diagnostic and Prognostic Tool for Prostate Cancer. International Journal of Cancer, 132, 2867-2875. [Google Scholar] [CrossRef] [PubMed]
[41] Hasegawa, T., Glavich, G.J., Pahuski, M., et al. (2018) Characterization and Evidence of the miR-888 Cluster as a Novel Cancer Network in Prostate. Molecular Cancer Re-search, 16, 669-681. [Google Scholar] [CrossRef] 
[42] Dai, Y. and Gao, X. (2021) Inhibition of Cancer Cell-Derived Exosomal microRNA-183 Suppresses Cell Growth and Metastasis in Prostate Cancer by Upregulating TPM1. Cancer Cell International, 21, Article No. 145. [Google Scholar] [CrossRef] [PubMed]
[43] 辛以军, 徐蓬永, 栾建波. miR-92a靶向调控STARD13表达促进前列腺癌DU145细胞侵袭和迁移的实验研究[J]. 河北医药, 2021, 43(15): 2260-2264.
[44] 刘绍祖, 黄晓华. 前列腺癌组织中miR-449a、miR-493-5p表达与临床病理参数及预后的关系[J]. 中国性科学, 2021, 30(7): 33-36.
[45] Jiang, S., Mo, C., Guo, S., et al. (2019) Human Bone Marrow Mesenchymal Stem Cells-Derived mi-croRNA-205- Containing Exosomes Impede the Progression of Prostate Cancer through Suppression of RHPN2. Jour-nal of Experimental & Clinical Cancer Research, 38, Article No. 495. [Google Scholar] [CrossRef] [PubMed]
[46] 李正平, 翟高杰. miR-299-5p在前列腺癌中的表达及对细胞生物行为学的影响[J]. 中国免疫学杂志, 2021, 37(9): 1088-1093.
[47] Guo, C., Liu, J., Zhou, Q., et al. (2020) Exo-somal Noncoding RNAs and Tumor Drug Resistance. Cancer Research, 80, 4307-4313. [Google Scholar] [CrossRef] 
[48] Zhang, Y., Zhao, J., Ding, M., et al. (2020) Loss of Exo-somal miR-146a-5p from Cancer-Associated Fibroblasts after Androgen Deprivation Therapy Contributes to Prostate Cancer Metastasis. Journal of Experimental & Clinical Cancer Research, 39, Article No. 282. [Google Scholar] [CrossRef] [PubMed]
[49] Li, J., Yang, X., Guan, H., et al. (2016) Exosome-Derived mi-croRNAs Contribute to Prostate Cancer Chemoresistance. International Journal of Oncology, 49, 838-846. [Google Scholar] [CrossRef] [PubMed]
[50] Corcoran, C., Rani, S. and O’Driscoll, L. (2014) miR-34a Is an Intra-cellular and Exosomal Predictive Biomarker for Response to Docetaxel with Clinical Relevance to Prostate Cancer Pro-gression. Prostate, 74, 1320-1334. [Google Scholar] [CrossRef] [PubMed]
[51] Hoey, C., Ray, J., Jeon, J., et al. (2018) miRNA-106a and Prostate Cancer Radioresistance: A Novel Role for LITAF in ATM Regulation. Molecular Oncology, 12, 1324-1341. [Google Scholar] [CrossRef] [PubMed]
[52] Duan, X.M., Liu, X.N., Li, Y.X., et al. (2019) MicroRNA-498 Promotes Proliferation, Migration, and Invasion of Prostate Cancer Cells and Decreases Radiation Sensitivity by Target-ing PTEN. The Kaohsiung Journal of Medical Sciences, 35, 659-671. [Google Scholar] [CrossRef] [PubMed]
[53] 董青川, 张治国, 程继, 等. miR-155对前列腺癌放射治疗的增敏作用[J]. 武警医学, 2017, 28(1): 60-63, 67.

为你推荐